| Literature DB >> 30857182 |
Consolación Garcia-Contreras1, Marta Vazquez-Gomez2, Alicia Barbero3, José Luis Pesantez4,5, Angelo Zinellu6, Fiammetta Berlinguer7, Pedro Gonzalez-Añover8, Jorge Gonzalez9, Teresa Encinas10, Laura Torres-Rovira11, Yolanda Nuñez12, Jaime Ballesteros13, Miriam Ayuso14, Susana Astiz15, Beatriz Isabel16, Cristina Ovilo17, Antonio Gonzalez-Bulnes18,19.
Abstract
The use of polyphenols is a promising strategy for preventing or alleviating intrauterine growth restriction (IUGR) because polyphenol supplementation increases plasma antioxidant capacity and improves oxidative stress at the feto-placental unit; which are recognized as main issues in IUGR. However, there is a scarcity of experimental data on both realistic benefits and potential hazards of polyphenol supplementation during gestation. Hence, we aimed to use a swine model of IUGR pregnancy to determine possible effects of maternal supplementation with polyphenols (hydroxytyrosol) on placental expression of genes involved in antioxidant homeostasis, vascularization and fetal growth and thus on antioxidant status, DNA-methylation and phenotypic traits (morphology and homeostasis) of the fetus. Hydroxytyrosol improves placental gene expression and fetal antioxidant status and glucose metabolism in a sex-dependent manner, in which males were favored in spite of developmental failures. Concomitantly, hydroxytyrosol prevented hypomethylation of DNA associated with oxidative stress. Finally, no major deleterious effects of hydroxytyrosol supplementation on constriction of the ductus arteriosus, a possible secondary effect of polyphenols during pregnancy, were found.Entities:
Keywords: antioxidants; intrauterine-growth-restriction; pregnancy; swine-model
Mesh:
Substances:
Year: 2019 PMID: 30857182 PMCID: PMC6429121 DOI: 10.3390/ijms20051187
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Maternal features at day of sampling (Day 100 of pregnancy). Mean values (±SEM) in treated (Hydroxytyrosol; Group HTX) and control sows (Group C). TEAC accounts for Trolox Equivalent Antioxidant Capacity, HDL-c for high-density lipoproteins cholesterol and LDL-c for low-density lipoproteins cholesterol).
| Maternal Features | HTX | C |
|---|---|---|
| Body-Weight (Kg) | 94.7 ± 3.8 | 98.6 ± 6.9 |
| Back-fat depth (cm) | 1.9 ± 0.1 | 2.2 ± 0.3 |
| TEAC (mmol/L) | 5.6 ± 0.1 | 5.6 ± 0.1 |
| Glutathione (µmol/L) | 383.4 ± 49.8 | 388.3 ± 108.9 |
| Glycine (µmol/L) | 805.5 ± 25.5 | 757.1 ± 34.7 |
| Taurine (µmol/L) | 106.2 ± 23.1 | 83.3 ± 9.4 |
| Serine (µmol/L) | 154.2 ± 19.6 | 140.5 ± 21.6 |
| Glucose (mg/dL) | 97.5 ± 3.9 | 96.8 ± 3.7 |
| Fructosamine (mg/dL) | 321.7 ± 22.4 | 308.1 ± 15.5 |
| Triglycerides (mg/dL) | 35.3 ± 3.6 | 33.1 ± 2.9 |
| Total cholesterol (mg/dL) | 75.7 ± 7.5 | 66.6 ± 5.0 |
| HDL-cholesterol (mg/dL) | 28.4 ± 1.9 | 25.6 ± 1.1 |
| LDL-cholesterol (mg/dL) | 38.5 ± 4.6 | 33.2 ± 2.9 |
Figure 1Relative gene expression of antioxidant, vascularization and fetal growth candidate genes in placenta of Iberian fetus from sows supplemented with hydroxytyrosol (HTX) and controls (C).
Fetal antioxidant status at day of sampling (Day 100 of pregnancy). Mean values (±SEM) and differences for sexes in treated (Hydroxytyrosol; Group HTX) and control fetuses (Group C). TEAC accounts for Trolox Equivalent Antioxidant Capacity. Superscript letters indicate significant differences between groups: a ≠ b: p < 0.9, c ≠ d: p < 0.05, e ≠ f: p < 0.01, g ≠ h: p < 0.005.
| Parameter | HTX | C | ||||
|---|---|---|---|---|---|---|
| Mean | Female | Male | Mean | Female | Male | |
| TEAC (mmol/L) | 2.2 ± 0.05 g | 2.1 ± 0.07 | 2.3 ± 0.08 | 2.1 ± 0.04 h | 2.2 ± 0.06 | 2.1 ± 0.07 |
| Glutathione (µmol/L) | 390.2 ± 15.9 a | 389.7 ± 19.1 | 395.7 ± 23.5 | 354.7 ± 17.9 a | 374.6 ± 25.6 | 338.4 ± 38.7 |
| Glycine (µmol/L) | 691.9 ± 32.1 c | 718.3 ± 14.1 | 661.3 ± 17.4 | 770.5 ± 26.6 d | 797.3 ± 50.8 | 730.4 ± 62.3 |
| Serine (µmol/L) | 262.9 ± 8.1 | 281.4 ± 10.8 | 237.9 ± 9.5 | 291.1 ± 17.7 | 306.1 ± 28.7 | 271.7 ± 16.4 |
| Taurine (µmol/L) | 304.1 ± 21.5 | 311.7 ± 19.3 | 286.9 ± 23.8 | 320.9 ± 17.8 | 314.1 ± 31.7 | 320.6 ± 38.2 |
Fetal development at day of sampling (Day 100 of pregnancy). Mean values (±SEM) and differences for sexes in treated (Hydroxytyrosol; Group HTX) and control fetuses (Group C). CRL accounts for Crown-rump Length, ONL for Occipito-Nasal Length, BPD for Biparietal Diameter, TC for Thoracic Circumference and AC for Abdominal Circumference. Superscript letters indicate significant differences between groups: a ≠ b: p < 0.9, c ≠ d: p < 0.05, e ≠ f: p < 0.01, g ≠ h: p < 0.005.
| Parameter | HTX | C | ||||
|---|---|---|---|---|---|---|
| Mean | Female | Male | Mean | Female | Male | |
| CRL | 21.3 ± 0.2 | 21.3 ± 0.3 | 21.6 ± 0.3 | 21.4 ± 0.2 | 21.2 ± 0.4 | 21.8 ± 0.4 |
| ONL | 11.8 ± 0.1 | 11.7 ± 0.1 | 11.6 ± 0.2 | 11.4 ± 0.1 | 11.4 ± 0.1 | 11.5 ± 0.2 |
| BPD | 4.1 ± 0.1 g | 4.1 ± 0.1 | 4.0 ± 0.1 | 4.2 ± 0.1 h | 4.2 ± 0.1 | 4.3 ± 0.1 |
| TC | 17.1 ± 0.2 | 17.1 ± 0.2 | 16.9 ± 0.4 | 17.5 ± 0.2 | 17.2 ± 0.4 | 18.2 ± 0.3 |
| AC | 14.1 ± 0.3 | 14.1 ± 0.3 | 13.9 ± 0.4 | 14.3 ± 0.2 | 14.2 ± 0.4 | 14.4 ± 0.3 |
| Body-weight | 668.3 ± 18.4 e | 656.1 ± 21.0 | 667.4 ± 30.3 | 736.3 ± 15.5 f | 702.2 ± 24.3 | 765.3 ± 26.9 |
| Viscerae | 102.5 ± 2.8 c | 104.5 ± 3.7 | 99.8 ± 4.5 | 114.5 ± 3.7 d | 113.1 ± 4.5 | 116.3 ± 6.2 |
| Brain | 25.4 ± 0.6 | 25.8 ± 0.3 | 24.8 ± 1.5 | 25.4 ± 0.3 | 25.4 ± 0.4 | 25.4 ± 0.4 |
| Heart | 6.4 ± 0.2 | 6.3 ± 0.3 | 6.5 ± 0.3 | 6.7 ± 0.2 | 6.5 ± 0.3 | 7.0 ± 0.3 |
| Lungs | 22.6 ± 0.8 c | 22.3 ± 0.8 | 22.9 ± 1.5 | 24.9 ± 0.8 d | 23.7 ± 1.0 | 26.4 ± 1.0 |
| Liver | 19.2 ± 0.6 c | 19.3 ± 0.7 | 18.9 ± 1.1 | 20.9 ± 0.6 d | 20.2 ± 0.8 | 21.8 ± 0.8 |
| Kidneys | 6.2 ± 0.2 | 6.2 ± 0.2 | 6.1 ± 0.3 | 6.5 ± 0.2 | 6.5 ± 0.3 | 6.7 ± 0.3 |
| Intestine | 27.7 ± 0.9 g | 27.9 ± 1.2 | 27.3 ± 1.6 | 32.0 ± 1.1 h | 31.3 ± 1.7 | 32.9 ± 1.3 |
| Pancreas | 0.8 ± 0.01 c | 0.8 ± 0.01 | 0.7 ± 0.01 | 0.9 ± 0.01 d | 0.9 ± 0.1 | 0.9 ± 0.1 |
| Spleen | 1.3 ± 0.1 | 1.2 ± 0.1 | 1.3 ± 0.1 | 1.3 ± 0.07 | 1.3 ± 0.1 | 1.4 ± 0.1 |
| Adrenal | 0.1 ± 0.01 | 0.1 ± 0.01 | 0.1 ± 0.01 | 0.1 ± 0.01 | 0.1 ± 0.01 | 0.1 ± 0.01 |
| Placenta | 249.3 ± 10.3 | 237.6 ± 10.7 | 265.4 ± 19.1 | 271.8 ± 8.9 | 265.3 ± 11.5 | 280.2 ± 14.0 |
Figure 2This image shows an apparent narrowing of the ductus arteriosus. DAo: Descending Aorta; DA: Ductus arteriosus; PA: Pulmonary Artery.
Fetal muscle fibers at day of sampling (Day 100 of pregnancy). Mean values (±SEM) and differences for sexes for the number of secondary fibers (F2) and the area of the muscle fiber in treated (Hydroxytyrosol; Group HTX) and control fetuses (Group C).
| Parameter | HTX | C | ||||
|---|---|---|---|---|---|---|
| Mean | Female | Male | Mean | Female | Male | |
| F2 | 30.1 ± 0.7 | 29.9 ± 1.0 | 31.8 ± 0.8 | 29.7 ± 0.8 | 32.0 ± 0.9 | 25.9 ± 1.4 |
| Area | 9.8 ± 0.3 | 9.6 ± 0.5 | 10.0 ± 0.4 | 10.4 ± 0.5 | 10.9 ± 0.6 | 7.9 ± 0.4 |
Fetal metabolic status at day of sampling (Day 100 of pregnancy). Mean values (±SEM) and differences for sexes in treated (Hydroxytyrosol; Group HTX) and control fetuses (Group C). HDL-c for high-density lipoproteins cholesterol and LDL-c for low-density lipoproteins cholesterol). Superscript letters indicate significant differences between groups: a ≠ b: p < 0.9, c ≠ d: p < 0.05, e ≠ f: p < 0.01, g ≠ h: p < 0.005.
| Parameter | HTX | C | ||||
|---|---|---|---|---|---|---|
| Mean | Female | Male | Mean | Female | Male | |
| Glucose | 123.6 ± 14.0 c | 133.2 ± 20.2 | 110.5 ± 18.4 | 177.6 ± 19.8 d | 200.2 ± 27.8 | 148.2 ± 27.0 |
| Fructosamine | 187.2 ± 3.5 e | 183.6 ± 4.5 | 192.1 ± 5.4 | 167.5 ± 6.0 f | 174.5 ± 6.8 | 158.3 ± 10.5 |
| Triglycerides | 47.6 ± 1.4 | 47.6 ± 1.8 | 47.5 ± 2.1 | 52.5 ± 2.6 | 53.6 ± 3.4 | 50.9 ± 3.9 |
| Total Cholesterol | 60.3 ± 1.7 | 59.7 ± 2.2 | 61.0 ± 2.9 | 59.6 ± 2.0 | 59.6 ± 2.4 | 59.7 ± 3.4 |
| HDL-c | 20.9 ± 0.5 | 21.1 ± 0.6 | 20.7 ± 0.8 | 22.6 ± 2.8 | 20.2 ± 0.6 | 25.6 ± 6.4 |
| LDL-c | 28.8 ± 1.1 | 28.5 ± 1.5 | 29.2 ± 1.8 | 31.3 ± 1.1 | 30.8 ± 1.5 | 32.0 ± 1.7 |
Figure 3The image shows gray scale normal appearance of the ductus arteriosus. DAo: Descending Aorta; DA: Ductus arteriosus; PA: Pulmonary Artery.
Primer design for qPCR and PCR efficiencies.
| Gene Symbol | Gene Name | Reference Sequence ID | Primer Sequences | Amplicon Length (bp) | Efficiency (%) |
|---|---|---|---|---|---|
|
| Catalase | NM_214301.2 | TGGCCCCATGTGCTTTCA | 209 | 83.75 |
|
| Superoxide dismutase 1 | NM_001190422 | GTGACTGCTGGCAAAGATGGTGTG | 158 | 89.75 |
|
| Hypoxia inducible factor 1 subunit alpha | NM_001123124.1 | GGCGGCGCGAACGACAAGA | 195 | 93.8 |
|
| Nitric oxide synthase 2 | XM_013981169.2 | TGGGGCAGCGGGATGACTTTC | 231 | 77.05 |
|
| Vascular endothelial growth factor A | NM_214084.1 | CATCTTCAAGCCGTCCTGTGT | 211 | 92.1 |
|
| Insulin like growth factor 1 | XM_005664199.3 | TGCGGAGACAGGGGCTTTTATTTC | 199 | 88.1 |
|
| Uncoupling protein 2 | ENSSSCG00000014833 | CCCTGCGGCCCGGACACATAG | 217 | 86.25 |
|
| Beta-actin | XM_003124280.4 | TCTGGCACCACACCTTCT | 114 | 89.35 |
|
| Beta-2-microglobulin | NM_213978.1 | TTCACACCGCTCCAGTAG | 166 | 83 |